FI82696C - Foerfarande foer framstaellning av farmakologiskt vaerdefulla pteridiner. - Google Patents
Foerfarande foer framstaellning av farmakologiskt vaerdefulla pteridiner. Download PDFInfo
- Publication number
- FI82696C FI82696C FI854862A FI854862A FI82696C FI 82696 C FI82696 C FI 82696C FI 854862 A FI854862 A FI 854862A FI 854862 A FI854862 A FI 854862A FI 82696 C FI82696 C FI 82696C
- Authority
- FI
- Finland
- Prior art keywords
- group
- phenyl
- pteridine
- yield
- melting point
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 8
- 238000002360 preparation method Methods 0.000 title claims description 6
- 230000000144 pharmacologic effect Effects 0.000 title description 5
- -1 pyrrolidino, piperidino, morpholino, thiomorpholino, 1-oxidothiomorpholino Chemical group 0.000 claims description 95
- 150000001875 compounds Chemical class 0.000 claims description 26
- 239000002253 acid Substances 0.000 claims description 22
- 150000003839 salts Chemical class 0.000 claims description 20
- 125000000217 alkyl group Chemical group 0.000 claims description 8
- 125000004432 carbon atom Chemical group C* 0.000 claims description 6
- 150000007524 organic acids Chemical class 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 125000006239 protecting group Chemical group 0.000 claims description 6
- 150000003195 pteridines Chemical class 0.000 claims description 6
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 5
- 150000007522 mineralic acids Chemical class 0.000 claims description 5
- 125000005843 halogen group Chemical group 0.000 claims description 4
- 125000004193 piperazinyl group Chemical group 0.000 claims description 4
- 125000003282 alkyl amino group Chemical group 0.000 claims description 3
- 150000001412 amines Chemical class 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- CYMCSLFWXQJBHU-UHFFFAOYSA-N n-benzyl-6-phenyl-2-piperazin-1-yl-4-thiomorpholin-4-ylpteridin-7-amine Chemical compound C=1C=CC=CC=1CNC(C(=NC1=2)C=3C=CC=CC=3)=NC1=NC(N1CCNCC1)=NC=2N1CCSCC1 CYMCSLFWXQJBHU-UHFFFAOYSA-N 0.000 claims description 3
- 125000005505 thiomorpholino group Chemical group 0.000 claims description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 230000000269 nucleophilic effect Effects 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 135
- 238000002844 melting Methods 0.000 description 76
- 230000008018 melting Effects 0.000 description 76
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 22
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 18
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 15
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 12
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 12
- 150000002168 ethanoic acid esters Chemical class 0.000 description 11
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 10
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 10
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 8
- 229960000583 acetic acid Drugs 0.000 description 8
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000012362 glacial acetic acid Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000012074 organic phase Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 5
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 229940093915 gynecological organic acid Drugs 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 235000005985 organic acids Nutrition 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 229910052938 sodium sulfate Inorganic materials 0.000 description 4
- 235000011152 sodium sulphate Nutrition 0.000 description 4
- WSYXJPXVIWXEKQ-UHFFFAOYSA-N 4-(2,7-dichloro-6-phenylpteridin-4-yl)thiomorpholine Chemical compound C=12N=C(C=3C=CC=CC=3)C(Cl)=NC2=NC(Cl)=NC=1N1CCSCC1 WSYXJPXVIWXEKQ-UHFFFAOYSA-N 0.000 description 3
- LDXZXENTEQVNJT-UHFFFAOYSA-N 4-(7-chloro-4-morpholin-4-yl-6-phenylpteridin-2-yl)piperazine-1-carbaldehyde Chemical compound C=12N=C(C=3C=CC=CC=3)C(Cl)=NC2=NC(N2CCN(CC2)C=O)=NC=1N1CCOCC1 LDXZXENTEQVNJT-UHFFFAOYSA-N 0.000 description 3
- GAWKTFFNBBOGFS-UHFFFAOYSA-N 4-[7-chloro-4-(1-oxo-1,4-thiazinan-4-yl)-6-phenylpteridin-2-yl]piperazine-1-carbaldehyde Chemical compound C=12N=C(C=3C=CC=CC=3)C(Cl)=NC2=NC(N2CCN(CC2)C=O)=NC=1N1CCS(=O)CC1 GAWKTFFNBBOGFS-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000007059 acute toxicity Effects 0.000 description 3
- 231100000403 acute toxicity Toxicity 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- CPNGPNLZQNNVQM-UHFFFAOYSA-N pteridine Chemical compound N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- RIBWUHCWCPYSQW-UHFFFAOYSA-N 2-piperazin-1-ylpteridine Chemical class C1CNCCN1C1=NC=C(N=CC=N2)C2=N1 RIBWUHCWCPYSQW-UHFFFAOYSA-N 0.000 description 2
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
- GJBIGLFKYRNPRQ-UHFFFAOYSA-N 4-(2,7-dichloro-6-phenylpteridin-4-yl)morpholine Chemical compound C=12N=C(C=3C=CC=CC=3)C(Cl)=NC2=NC(Cl)=NC=1N1CCOCC1 GJBIGLFKYRNPRQ-UHFFFAOYSA-N 0.000 description 2
- SWQVUKRKXPTFJY-UHFFFAOYSA-N 4-(2,7-dichloropteridin-4-yl)morpholine Chemical compound N=1C(Cl)=NC2=NC(Cl)=CN=C2C=1N1CCOCC1 SWQVUKRKXPTFJY-UHFFFAOYSA-N 0.000 description 2
- CEQDHZLUCKTZDQ-UHFFFAOYSA-N 4-(2-chloro-4-morpholin-4-ylpteridin-7-yl)morpholine Chemical compound C=12N=CC(N3CCOCC3)=NC2=NC(Cl)=NC=1N1CCOCC1 CEQDHZLUCKTZDQ-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- GLAMJFYGEMODFF-UHFFFAOYSA-N 4-[7-(benzylamino)-6-phenyl-4-thiomorpholin-4-ylpteridin-2-yl]piperazine-1-carbaldehyde Chemical compound C1CN(C=O)CCN1C1=NC(N2CCSCC2)=C(N=C(C(NCC=2C=CC=CC=2)=N2)C=3C=CC=CC=3)C2=N1 GLAMJFYGEMODFF-UHFFFAOYSA-N 0.000 description 2
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 230000002001 anti-metastasis Effects 0.000 description 2
- 230000002785 anti-thrombosis Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- UXVXHECNJUECPO-UHFFFAOYSA-N n,n-dimethyl-6-phenyl-2-piperazin-1-yl-4-pyrrolidin-1-ylpteridin-7-amine Chemical compound C=12N=C(C=3C=CC=CC=3)C(N(C)C)=NC2=NC(N2CCNCC2)=NC=1N1CCCC1 UXVXHECNJUECPO-UHFFFAOYSA-N 0.000 description 2
- KNDYYVVEFVWOOT-UHFFFAOYSA-N n-benzyl-2-chloro-4-piperidin-1-ylpteridin-7-amine Chemical compound C=12N=CC(NCC=3C=CC=CC=3)=NC2=NC(Cl)=NC=1N1CCCCC1 KNDYYVVEFVWOOT-UHFFFAOYSA-N 0.000 description 2
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- YHIIJNLSGULWAA-UHFFFAOYSA-N 1,4-thiazinane 1-oxide Chemical compound O=S1CCNCC1 YHIIJNLSGULWAA-UHFFFAOYSA-N 0.000 description 1
- MSSDTZLYNMFTKN-UHFFFAOYSA-N 1-Piperazinecarboxaldehyde Chemical compound O=CN1CCNCC1 MSSDTZLYNMFTKN-UHFFFAOYSA-N 0.000 description 1
- NWBJBMHJBACYGT-UHFFFAOYSA-N 2,4,7-trichloro-6-phenylpteridine Chemical compound ClC1=NC2=NC(Cl)=NC(Cl)=C2N=C1C1=CC=CC=C1 NWBJBMHJBACYGT-UHFFFAOYSA-N 0.000 description 1
- VQPKNENUIGMHNU-UHFFFAOYSA-N 2,4,7-trichloropteridine Chemical compound ClC1=NC(Cl)=NC2=NC(Cl)=CN=C21 VQPKNENUIGMHNU-UHFFFAOYSA-N 0.000 description 1
- RGKRHWLTEUVZHM-UHFFFAOYSA-N 2,7-dichloro-6-phenyl-4-piperidin-1-ylpteridine Chemical compound C=12N=C(C=3C=CC=CC=3)C(Cl)=NC2=NC(Cl)=NC=1N1CCCCC1 RGKRHWLTEUVZHM-UHFFFAOYSA-N 0.000 description 1
- ILYDCKYNGFVQHZ-UHFFFAOYSA-N 2,7-dichloro-N,N-dimethyl-6-phenylpteridin-4-amine Chemical compound ClC1=NC2=NC(=C(N=C2C(=N1)N(C)C)C1=CC=CC=C1)Cl ILYDCKYNGFVQHZ-UHFFFAOYSA-N 0.000 description 1
- OJERFWUAMPYEMC-UHFFFAOYSA-N 2-[[7-(benzylamino)-2-chloropteridin-4-yl]-methylamino]ethanol Chemical compound C=1N=C2C(N(CCO)C)=NC(Cl)=NC2=NC=1NCC1=CC=CC=C1 OJERFWUAMPYEMC-UHFFFAOYSA-N 0.000 description 1
- MTJGVAJYTOXFJH-UHFFFAOYSA-N 3-aminonaphthalene-1,5-disulfonic acid Chemical compound C1=CC=C(S(O)(=O)=O)C2=CC(N)=CC(S(O)(=O)=O)=C21 MTJGVAJYTOXFJH-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- CKVPAYIYEWAHIB-UHFFFAOYSA-N 4-(2,7-dichloro-6-methyl-6H-pteridin-7-yl)morpholine Chemical compound ClC1=NC2=NC(C(N=C2C=N1)C)(N1CCOCC1)Cl CKVPAYIYEWAHIB-UHFFFAOYSA-N 0.000 description 1
- NSWWAJFJFVIFIY-UHFFFAOYSA-N 4-(2-chloro-6-methyl-4-morpholin-4-ylpteridin-7-yl)morpholine Chemical compound CC1=NC2=C(N3CCOCC3)N=C(Cl)N=C2N=C1N1CCOCC1 NSWWAJFJFVIFIY-UHFFFAOYSA-N 0.000 description 1
- NLYWGPYBUHRLLS-UHFFFAOYSA-N 4-(2-chloro-6-methyl-7-thiomorpholin-4-ylpteridin-4-yl)morpholine Chemical compound CC1=NC2=C(N3CCOCC3)N=C(Cl)N=C2N=C1N1CCSCC1 NLYWGPYBUHRLLS-UHFFFAOYSA-N 0.000 description 1
- XGWVNQNSJQGULB-UHFFFAOYSA-N 4-(4-morpholin-4-yl-2-piperazin-1-ylpteridin-7-yl)morpholine Chemical compound C1CNCCN1C1=NC(N2CCOCC2)=C(N=CC(=N2)N3CCOCC3)C2=N1 XGWVNQNSJQGULB-UHFFFAOYSA-N 0.000 description 1
- DUWXBAYNTVXXPX-UHFFFAOYSA-N 4-(6-methyl-2-piperazin-1-yl-7-thiomorpholin-4-ylpteridin-4-yl)morpholine Chemical compound CC1=NC2=C(N3CCOCC3)N=C(N3CCNCC3)N=C2N=C1N1CCSCC1 DUWXBAYNTVXXPX-UHFFFAOYSA-N 0.000 description 1
- JYKRPHPHUQAIPZ-UHFFFAOYSA-N 4-(7-chloro-6-phenyl-4-pyrrolidin-1-ylpteridin-2-yl)piperazine-1-carbaldehyde Chemical compound C=12N=C(C=3C=CC=CC=3)C(Cl)=NC2=NC(N2CCN(CC2)C=O)=NC=1N1CCCC1 JYKRPHPHUQAIPZ-UHFFFAOYSA-N 0.000 description 1
- DAUCBPOTMUPLBF-UHFFFAOYSA-N 4-(7-chloro-6-phenyl-4-thiomorpholin-4-ylpteridin-2-yl)piperazine-1-carbaldehyde Chemical compound C=12N=C(C=3C=CC=CC=3)C(Cl)=NC2=NC(N2CCN(CC2)C=O)=NC=1N1CCSCC1 DAUCBPOTMUPLBF-UHFFFAOYSA-N 0.000 description 1
- QHHLKOCFSWZNRA-UHFFFAOYSA-N 4-(7-morpholin-4-yl-6-phenyl-2-piperazin-1-ylpteridin-4-yl)-1,4-thiazinane 1-oxide Chemical compound O1CCN(CC1)C1=C(N=C2C(=NC(=NC2=N1)N1CCNCC1)N1CCS(CC1)=O)C1=CC=CC=C1 QHHLKOCFSWZNRA-UHFFFAOYSA-N 0.000 description 1
- BAUOJBQIZRQWRY-UHFFFAOYSA-N 4-[4-[benzyl(methyl)amino]-7-(dimethylamino)-6-phenylpteridin-2-yl]piperazine-1-carbaldehyde Chemical compound C=12N=C(C=3C=CC=CC=3)C(N(C)C)=NC2=NC(N2CCN(CC2)C=O)=NC=1N(C)CC1=CC=CC=C1 BAUOJBQIZRQWRY-UHFFFAOYSA-N 0.000 description 1
- RQSVNURXHGGPTO-UHFFFAOYSA-N 4-[4-[benzyl(methyl)amino]-7-chloro-6-phenylpteridin-2-yl]piperazine-1-carbaldehyde Chemical compound N=1C(N2CCN(CC2)C=O)=NC2=NC(Cl)=C(C=3C=CC=CC=3)N=C2C=1N(C)CC1=CC=CC=C1 RQSVNURXHGGPTO-UHFFFAOYSA-N 0.000 description 1
- CUNLKSCXVUNDRS-UHFFFAOYSA-N 4-[4-[benzyl(methyl)amino]-7-morpholin-4-yl-6-phenylpteridin-2-yl]piperazine-1-carbaldehyde Chemical compound N=1C(N2CCN(CC2)C=O)=NC2=NC(N3CCOCC3)=C(C=3C=CC=CC=3)N=C2C=1N(C)CC1=CC=CC=C1 CUNLKSCXVUNDRS-UHFFFAOYSA-N 0.000 description 1
- MOBNUSJJGHFPFQ-UHFFFAOYSA-N 4-[6-phenyl-4,7-di(piperidin-1-yl)pteridin-2-yl]piperazine-1-carbaldehyde Chemical compound C1CN(C=O)CCN1C1=NC(N2CCCCC2)=C(N=C(C=2C=CC=CC=2)C(=N2)N3CCCCC3)C2=N1 MOBNUSJJGHFPFQ-UHFFFAOYSA-N 0.000 description 1
- YSNVSBCVZNWKGH-UHFFFAOYSA-N 4-[7-(1-oxo-1,4-thiazinan-4-yl)-6-phenyl-2-piperazin-1-ylpteridin-4-yl]-1,4-thiazinane 1-oxide Chemical compound O=S1CCN(CC1)C1=NC(=NC2=NC(=C(N=C12)C1=CC=CC=C1)N1CCS(CC1)=O)N1CCNCC1 YSNVSBCVZNWKGH-UHFFFAOYSA-N 0.000 description 1
- VSWBGFWNGWRKDM-UHFFFAOYSA-N 4-[7-chloro-4-(dimethylamino)-6-phenylpteridin-2-yl]piperazine-1-carbaldehyde Chemical compound ClC1=C(N=C2C(=NC(=NC2=N1)N1CCN(CC1)C=O)N(C)C)C1=CC=CC=C1 VSWBGFWNGWRKDM-UHFFFAOYSA-N 0.000 description 1
- XXSIXQDELMYCTC-UHFFFAOYSA-N 4-n,4-n,7-n,7-n-tetramethyl-6-phenyl-2-piperazin-1-ylpteridine-4,7-diamine Chemical compound CN(C)C1=NC2=NC(N3CCNCC3)=NC(N(C)C)=C2N=C1C1=CC=CC=C1 XXSIXQDELMYCTC-UHFFFAOYSA-N 0.000 description 1
- CKISRHNGYULHGI-UHFFFAOYSA-N 4-n,7-n-dibenzyl-4-n,7-n-dimethyl-6-phenyl-2-piperazin-1-ylpteridine-4,7-diamine Chemical compound N=1C2=NC(N3CCNCC3)=NC(N(C)CC=3C=CC=CC=3)=C2N=C(C=2C=CC=CC=2)C=1N(C)CC1=CC=CC=C1 CKISRHNGYULHGI-UHFFFAOYSA-N 0.000 description 1
- YNYOHBFWUQAWQW-UHFFFAOYSA-N 4-pteridin-2-ylmorpholine Chemical compound C1COCCN1C1=NC=C(N=CC=N2)C2=N1 YNYOHBFWUQAWQW-UHFFFAOYSA-N 0.000 description 1
- ZONQLDOFIRSPFE-UHFFFAOYSA-N 4-pteridin-2-ylpiperazine-1-carbaldehyde Chemical class C1CN(C=O)CCN1C1=NC=C(N=CC=N2)C2=N1 ZONQLDOFIRSPFE-UHFFFAOYSA-N 0.000 description 1
- FMXXMLPFAFDKKZ-UHFFFAOYSA-N 6-phenyl-2-piperazin-1-yl-4,7-di(piperidin-1-yl)pteridine Chemical compound C1CCCCN1C1=NC2=NC(N3CCNCC3)=NC(N3CCCCC3)=C2N=C1C1=CC=CC=C1 FMXXMLPFAFDKKZ-UHFFFAOYSA-N 0.000 description 1
- LYHHTUKHEGOSDZ-UHFFFAOYSA-N 6-phenyl-2-piperazin-1-ylpteridine Chemical compound C1(=CC=CC=C1)C=1N=C2C=NC(=NC2=NC=1)N1CCNCC1 LYHHTUKHEGOSDZ-UHFFFAOYSA-N 0.000 description 1
- LLSMNKXJGLPMIW-UHFFFAOYSA-N 6-phenylpteridine Chemical compound C1=CC=CC=C1C1=CN=C(N=CN=C2)C2=N1 LLSMNKXJGLPMIW-UHFFFAOYSA-N 0.000 description 1
- LQIUVTVMTMIEMP-UHFFFAOYSA-N 7-morpholin-4-ylpteridin-2-amine Chemical compound NC1=NC2=NC(=CN=C2C=N1)N1CCOCC1 LQIUVTVMTMIEMP-UHFFFAOYSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- RBWMPAVUDZMFDB-UHFFFAOYSA-N C(C1=CC=CC=C1)NC1=CN=C2C(=NC(=NC2=N1)Cl)N1CCS(CC1)=O.C(C)O Chemical compound C(C1=CC=CC=C1)NC1=CN=C2C(=NC(=NC2=N1)Cl)N1CCS(CC1)=O.C(C)O RBWMPAVUDZMFDB-UHFFFAOYSA-N 0.000 description 1
- SQASYVUHUJVWGK-UHFFFAOYSA-N C(C1=CC=CC=C1)NC1=NC(=NC2=NC(=CN=C12)N1CCS(CC1)=O)Cl.O1CCOCC1 Chemical compound C(C1=CC=CC=C1)NC1=NC(=NC2=NC(=CN=C12)N1CCS(CC1)=O)Cl.O1CCOCC1 SQASYVUHUJVWGK-UHFFFAOYSA-N 0.000 description 1
- HQVYAFWHUPPZEP-UHFFFAOYSA-N C(C1=CC=CC=C1)NC1=NC(N(C2=NC=CN=C12)N1CCS(CC1)=O)N1CCNCC1 Chemical compound C(C1=CC=CC=C1)NC1=NC(N(C2=NC=CN=C12)N1CCS(CC1)=O)N1CCNCC1 HQVYAFWHUPPZEP-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- BKHOYPFGMWTOJL-UHFFFAOYSA-N ClC1=NC2=NC(=C(N=C2C(=N1)N1CCOCC1)C)N1CCOCC1.C(C)O Chemical compound ClC1=NC2=NC(=C(N=C2C(=N1)N1CCOCC1)C)N1CCOCC1.C(C)O BKHOYPFGMWTOJL-UHFFFAOYSA-N 0.000 description 1
- BXQDVFIUGUTETD-UHFFFAOYSA-N ClC1=NC2=NC(=CN=C2C(=N1)NCC1=CC=CC=C1)Cl.C(C)O Chemical compound ClC1=NC2=NC(=CN=C2C(=N1)NCC1=CC=CC=C1)Cl.C(C)O BXQDVFIUGUTETD-UHFFFAOYSA-N 0.000 description 1
- GFUBTAJUEDVKNV-UHFFFAOYSA-N ClC1=NC2=NC=CN=C2C(=N1)N1CCS(CC1)=O Chemical compound ClC1=NC2=NC=CN=C2C(=N1)N1CCS(CC1)=O GFUBTAJUEDVKNV-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000764773 Inna Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- XMMFOLGAOPURJY-UHFFFAOYSA-N N-benzyl-4-(1-oxo-1,4-thiazinan-4-yl)-6-phenyl-2-piperazin-1-ylpteridin-7-amine Chemical compound C(C1=CC=CC=C1)NC1=C(N=C2C(=NC(=NC2=N1)N1CCNCC1)N1CCS(CC1)=O)C1=CC=CC=C1 XMMFOLGAOPURJY-UHFFFAOYSA-N 0.000 description 1
- SQYPTHMPHAUHSB-UHFFFAOYSA-N N-benzyl-N-methyl-7-morpholin-4-yl-6-phenyl-2-piperazin-1-ylpteridin-4-amine Chemical compound CN(C1=NC(=NC2=NC(=C(N=C12)C1=CC=CC=C1)N1CCOCC1)N1CCNCC1)CC1=CC=CC=C1 SQYPTHMPHAUHSB-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 240000006394 Sorghum bicolor Species 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- SXDBWCPKPHAZSM-UHFFFAOYSA-N bromic acid Chemical compound OBr(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-N 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 230000003073 embolic effect Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229940116364 hard fat Drugs 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000023589 ischemic disease Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- DXSGWJSZLBSYJQ-UHFFFAOYSA-N n-benzyl-2-chloro-7-(1-oxo-1,4-thiazinan-4-yl)pteridin-4-amine Chemical compound C=12N=CC(N3CCS(=O)CC3)=NC2=NC(Cl)=NC=1NCC1=CC=CC=C1 DXSGWJSZLBSYJQ-UHFFFAOYSA-N 0.000 description 1
- NNRYTKBMUOMWFL-UHFFFAOYSA-N n-benzyl-2-piperazin-1-yl-4-piperidin-1-ylpteridin-7-amine Chemical compound C=1C=CC=CC=1CNC(N=C1N=2)=CN=C1C(N1CCCCC1)=NC=2N1CCNCC1 NNRYTKBMUOMWFL-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 150000004965 peroxy acids Chemical class 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000012262 resinous product Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- ISPBABGJNLPGOY-UHFFFAOYSA-K zinc barium(2+) hydroxide sulfate Chemical compound [OH-].[Zn+2].[Ba+2].[O-]S([O-])(=O)=O ISPBABGJNLPGOY-UHFFFAOYSA-K 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
- C07D475/08—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE3445298 | 1984-12-12 | ||
| DE19843445298 DE3445298A1 (de) | 1984-12-12 | 1984-12-12 | Neue pteridine, verfahren zu ihrer herstellung und deren verwendung als zwischenprodukte oder als arzneimittel |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| FI854862A0 FI854862A0 (fi) | 1985-12-10 |
| FI854862A7 FI854862A7 (fi) | 1986-06-13 |
| FI82696B FI82696B (fi) | 1990-12-31 |
| FI82696C true FI82696C (fi) | 1991-04-10 |
Family
ID=6252576
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI854862A FI82696C (fi) | 1984-12-12 | 1985-12-10 | Foerfarande foer framstaellning av farmakologiskt vaerdefulla pteridiner. |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP0185259A3 (show.php) |
| JP (1) | JPS61140585A (show.php) |
| AU (1) | AU576924B2 (show.php) |
| CA (1) | CA1252783A (show.php) |
| DE (1) | DE3445298A1 (show.php) |
| DK (1) | DK161327C (show.php) |
| ES (1) | ES8707238A1 (show.php) |
| FI (1) | FI82696C (show.php) |
| GR (1) | GR852996B (show.php) |
| IL (1) | IL77294A (show.php) |
| NO (1) | NO161373C (show.php) |
| NZ (1) | NZ214522A (show.php) |
| PH (1) | PH24451A (show.php) |
| PT (1) | PT81650B (show.php) |
| ZA (1) | ZA859462B (show.php) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7276506B2 (en) | 1998-12-28 | 2007-10-02 | 4 Aza Bioscience Nv | Immunosuppressive effects of pteridine derivatives |
| EE200400043A (et) * | 2001-06-28 | 2004-10-15 | Essential Therapeutics, Inc. | Uudsed heterotsüklilised ühendid kui selektiivsedbakteriaalsed DHFR inhibiitorid ning nende kasutamine |
| DE10202468A1 (de) * | 2002-01-23 | 2004-09-30 | Faustus Forschungs Cie. Translational Cancer Research Gmbh | Pteridinderivate, Verfahren zu deren Herstellung und ihre Verwendung |
| DE602004009696T2 (de) * | 2003-08-29 | 2008-08-28 | 4 Aza Ip Nv | Immunosuppressive wirkungen von pteridinderivativen |
| GB2407089A (en) * | 2003-10-17 | 2005-04-20 | 4 Aza Bioscience Nv | Pteridine derivatives |
| ATE369862T1 (de) * | 2003-10-17 | 2007-09-15 | 4 Aza Ip Nv | Heterocyclus-substituierte pteridin-derivate und ihre verwendung in der therapie |
| WO2005087227A1 (en) * | 2004-03-04 | 2005-09-22 | Neurogen Corporation | Arylalkylamino-substituted quinazoline analogues |
| DE102004057595A1 (de) | 2004-11-29 | 2006-06-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Substituierte Pteridine zur Behandlung von entzündlichen Erkrankungen |
| DE102004057594A1 (de) | 2004-11-29 | 2006-06-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Substitueirte Pteridine zur Behandlung von entzündlichen Erkrankungen |
| DE102004057645A1 (de) * | 2004-11-29 | 2006-06-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Substituierte Pteridine zur Behandlung von entzündlichen Erkrankungen |
| DE102004057618A1 (de) | 2004-11-29 | 2006-06-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Substituierte Pteridine zur Behandlung von entzündlichen Erkrankungen |
| RU2445315C2 (ru) * | 2005-11-22 | 2012-03-20 | Кудос Фармасьютиклз Лимитед | ПРОИЗВОДНЫЕ ПИРИДО-, ПИРАЗО- И ПИРИМИДО-ПИРИМИДИНА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ mTOR |
| WO2007060404A1 (en) * | 2005-11-22 | 2007-05-31 | Kudos Pharmaceuticals Limited | PYRIDO-,PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS |
| JP5440934B2 (ja) | 2006-05-24 | 2014-03-12 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 置換プテリジン |
| US10144736B2 (en) | 2006-07-20 | 2018-12-04 | Gilead Sciences, Inc. | Substituted pteridines useful for the treatment and prevention of viral infections |
| WO2008009078A2 (en) | 2006-07-20 | 2008-01-24 | Gilead Sciences, Inc. | 4,6-dl- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections |
| WO2008023161A1 (en) | 2006-08-23 | 2008-02-28 | Kudos Pharmaceuticals Limited | 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors |
| MX2010014230A (es) | 2008-06-20 | 2011-03-29 | Astrazeneca Ab | Composiciones que contienen pirido [2,3-d] pirimidinas sustituidas con metilmorfolina y proceso relacionado. |
| WO2016141092A1 (en) | 2015-03-04 | 2016-09-09 | Gilead Sciences, Inc. | Toll-like receptor modulating 4,6-diamino-pyrido[3,2-d]pyrimidine compounds |
| EP3507276B1 (en) | 2016-09-02 | 2021-11-03 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
| US10640499B2 (en) | 2016-09-02 | 2020-05-05 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
| TWI751517B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TW202210480A (zh) | 2019-04-17 | 2022-03-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TWI879779B (zh) | 2019-06-28 | 2025-04-11 | 美商基利科學股份有限公司 | 類鐸受體調節劑化合物的製備方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3159628A (en) * | 1962-05-28 | 1964-12-01 | Smith Kline French Lab | Pteridine-5-oxide derivatives |
| DE3323932A1 (de) * | 1983-07-02 | 1985-01-10 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue 2-piperazino-pteridine, verfahren zu ihrer herstellung und diese verbindung enthaltende arzneimittel |
-
1984
- 1984-12-12 DE DE19843445298 patent/DE3445298A1/de not_active Withdrawn
-
1985
- 1985-12-05 EP EP85115459A patent/EP0185259A3/de not_active Ceased
- 1985-12-10 FI FI854862A patent/FI82696C/fi not_active IP Right Cessation
- 1985-12-11 DK DK572685A patent/DK161327C/da not_active IP Right Cessation
- 1985-12-11 PT PT81650A patent/PT81650B/pt not_active IP Right Cessation
- 1985-12-11 IL IL77294A patent/IL77294A/xx unknown
- 1985-12-11 JP JP60278859A patent/JPS61140585A/ja active Pending
- 1985-12-11 NO NO854965A patent/NO161373C/no unknown
- 1985-12-11 NZ NZ214522A patent/NZ214522A/xx unknown
- 1985-12-11 CA CA000497336A patent/CA1252783A/en not_active Expired
- 1985-12-11 ZA ZA859462A patent/ZA859462B/xx unknown
- 1985-12-11 PH PH33161A patent/PH24451A/en unknown
- 1985-12-11 ES ES549806A patent/ES8707238A1/es not_active Expired
- 1985-12-12 GR GR852996A patent/GR852996B/el unknown
- 1985-12-12 AU AU51232/85A patent/AU576924B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| FI854862A7 (fi) | 1986-06-13 |
| DK161327B (da) | 1991-06-24 |
| AU576924B2 (en) | 1988-09-08 |
| FI82696B (fi) | 1990-12-31 |
| GR852996B (show.php) | 1986-04-16 |
| NZ214522A (en) | 1988-07-28 |
| NO161373B (no) | 1989-05-02 |
| CA1252783A (en) | 1989-04-18 |
| DK161327C (da) | 1991-12-09 |
| DK572685D0 (da) | 1985-12-11 |
| ES549806A0 (es) | 1987-07-16 |
| ES8707238A1 (es) | 1987-07-16 |
| DE3445298A1 (de) | 1986-06-12 |
| EP0185259A2 (de) | 1986-06-25 |
| PT81650A (de) | 1986-01-01 |
| AU5123285A (en) | 1986-06-19 |
| FI854862A0 (fi) | 1985-12-10 |
| ZA859462B (en) | 1987-07-29 |
| NO161373C (no) | 1989-08-09 |
| IL77294A (en) | 1989-02-28 |
| DK572685A (da) | 1986-06-13 |
| PT81650B (pt) | 1988-04-21 |
| PH24451A (en) | 1990-06-25 |
| JPS61140585A (ja) | 1986-06-27 |
| EP0185259A3 (de) | 1989-03-01 |
| NO854965L (no) | 1986-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI82696C (fi) | Foerfarande foer framstaellning av farmakologiskt vaerdefulla pteridiner. | |
| FI80454C (fi) | Foerfarande foer framstaellning av farmakologiskt vaerdefulla 2-piperazino-pteridiner. | |
| CA1136133A (en) | 8-phenyl-purines, their preparation and their use as pharmaceutical compositions | |
| HU183087B (en) | Process for producing substituted pyrano- and thiopyrano-quinolines | |
| SU999972A3 (ru) | Способ получени производных пиридо-(1,2-а) пиримидина или их фармацевтически приемлемых солей,или их оптически активных изомеров | |
| EP0927184A1 (de) | 3-substituierte pyrido 4',3':4,5] thieno 2,3-d]pyrimidin-derivate, ihre herstellung und verwendung | |
| KR900005836B1 (ko) | 1,2,4-트리아조로[4,3-c]피리미딘 | |
| US4560685A (en) | 2-Piperazino-pteridines useful as antithrombotics and antimetastatics | |
| Abdel-Rahman et al. | SYNTHESIS OF SOME NEW THIENO [2, 3-b] PYRIDINES, PYRIDO [3′, 2′: 4, 5]-THIENO [3, 2-d] PYRIMIDINES AND PYRIDO [3′, 2′: 4, 5] THIENO [3, 2-d][1, 2, 3]-TRIAZINES | |
| FI61029B (fi) | Nytt foerfarande foer framstaellning av terapeutiskt anvaendbara dibenso(b,e)(1,4)diazepiner | |
| US3764598A (en) | Pyrimidopyridazine derivatives | |
| FI67220C (fi) | Foerfarande foer framstaellning av antitrombotiskt verkande 2-perhydro-1,4-diazino)-pyrimido(5,4-d)pyrimidiner | |
| Revanasiddappa et al. | Synthesis and biological studies of some novel schiff bases and hydrazones derived from 8-hydroxy quinoline moiety | |
| LeMahieu et al. | Synthesis and antiallergy activity of 5-oxo-5H-thiazolo [2, 3-b] quinazolinecarboxylic acids | |
| Janin et al. | A formal new access to the benzo [c] phenanthridine alkaloids, synthesis of nitidine and o-methyl fagaronine analogues. | |
| KR920000271B1 (ko) | 1,2,4-트리아조로[1,5-c] 피리미딘 및 이의 제조방법 | |
| US3467657A (en) | As-triazino(5,6-b)indoles | |
| US20040072856A1 (en) | 4-ANILINO[2,3-b]QUINOLINE DERIVATIVES,THEIR PREPARATION PROCECC ANDPHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | |
| Carbon et al. | Adjacent Nitro and Guanidino Groups. III. Preparation and Rearrangement of Some Pyrido [2, 3-e]-as-triazine 1-Oxides1 | |
| FI74467C (fi) | Foerfarande foer framstaellning av 1,2,3,10-tetrahydro-10-oxo-cyklopenta/d/pyrido/1,2-a/pyrimidin- och 1,2,3,4-tetrahydro-11-oxo-11h-pyrido/2,1-b/kinazolinderivat. | |
| Hassan et al. | Nucleophilic reactions of 1-substituted-2, 5-dithiobiureas with chlorinated benzo-and naphthoquinones as well as (1, 3-dioxo-2, 3-dihydro-1 (H)-inden-2-ylidene) propanedinitrile | |
| Temple Jr et al. | Methylation and amination of folic acid | |
| DeCroix et al. | Pteridines from. alpha.-phenyl-N, N-dimethylacetamidine | |
| KR101178495B1 (ko) | 3,6-이치환-4,5,6,7-테트라하이드로-1Ｈ-피라졸로［3,4-ｃ］피리딘-7-온 화합물과 이 화합물의 제조방법 | |
| IE920704A1 (en) | Nitrogen oxides of aza- and diaza-anthracenedione¹derivatives as antitumor agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM | Patent lapsed |
Owner name: DR. KARL THOMAE GESELLSCHAFT MIT |